Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications
Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications
复制标题
DOI：
10.1111/j.1365-2559.2011.03757.x
复制
发表时间：
2011-02-01
期刊：
影响因子：
6.4
通讯作者：
Hardisson, David
中科院分区：
文献类型：
--
作者：
Garcia-Fernandez, Eugenia;De Diego, Juan I.;Hardisson, David
目的：探讨Aurora B在喉鳞状细胞癌（LSCC）中的临床及预后意义。方法与结果：分析259例喉鳞状细胞癌中Aurora B蛋白的表达情况。还测定了增殖指数 (Ki67) 和其他细胞周期控制蛋白（例如 Aurora A、生存素和 p53）的表达。 Aurora B 在 55.4% 的 LSCC 中高表达。高 Aurora B 表达水平与肿瘤复发 (P = 0.01)、疾病死亡 (P = 0.05) 以及无病生存率 (P = 0.013) 和总生存率 (P = 0.04) 降低相关。生存素表达既与临床病理特征也不与生存相关。然而，细胞核中的存活蛋白表达与 Aurora B 表达平行（P = 0.014）。 Aurora A 表达与肿瘤分级的增加显着相关（P = 0.008）。多变量分析表明，Aurora B 是 LSCC 特异性无病生存率的独立预测因子 [风险比 (HR)，2.10； 95% 置信区间 (95% CI)，1.25-3.52 (P = 0.005)] 和总生存率 [HR，1.91； 95% CI 1.01-3.34 (P = 0.023)]。结论：Aurora B 可能是 LSCC 的一种新型预后生物标志物，也是此类肿瘤的潜在治疗靶点。
Aims:To investigate the clinical and prognostic significance of Aurora B in laryngeal squamous cell carcinomas (LSCC).Methods and results:Aurora B protein expression was analysed in 259 LSCC. The proliferation index (Ki67) and the expression of other cell cycle control proteins, such as Aurora A, survivin and p53 was also determined. Aurora B was highly expressed in 55.4% of LSCC. High Aurora B expression levels were correlated with tumour recurrence (P = 0.01), death from disease (P = 0.05) and decreased disease-free survival (P = 0.013) and overall survival (P = 0.04). Survivin expression was neither associated with clinicopathological characteristics nor with survival. However, survivin expression in the nucleus paralleled Aurora B expression (P = 0.014). Aurora A expression was associated significantly with increased tumour grade (P = 0.008). Multivariate analysis indicated that Aurora B was an independent predictor for LSCC-specific disease-free survival [hazard ratio (HR), 2.10; 95% confidence interval (95% CI), 1.25-3.52 (P = 0.005)] and overall survival [HR, 1.91; 95% CI 1.01-3.34 (P = 0.023)].Conclusions:Aurora B may be a novel prognostic biomarker for LSCC and a potential therapeutic target in this type of tumour.